Exai Bio Analysis
What is Exai Bio?
Exai Bio uses a proprietary RNA-based liquid biopsy platform to detect cancer from blood samples. The platform combines novel oncRNA biomarkers with AI to identify cancer signals hidden in noise. This enables early, accurate diagnosis with insights into cancer biology.
Location
Palo Alto, United States
Employees
11-50
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- Proprietary oncRNA biomarkers
- AI-powered cancer signal detection
- Early cancer diagnosis from blood samples
- Clinical insights into cancer biology
Use Cases
Detect cancer in pre-symptomatic patients; Identify cancer signals in blood samples with high sensitivity; Provide clinical insights into tumor biology; Enable early intervention before symptoms appear; Diagnose cancer with accuracy surpassing traditional methods
Other Considerations
Founded with technology from UCSF's Dr. Hani Goodarzi lab; Veteran leaders in RNA biology and AI/ML from academia and industry; Backed by Section 32, Casdin Capital, and Two Sigma Ventures; HQ in Palo Alto, CA
See something that needs updating? Suggest edits to this profile.